Subtype and genotypic resistance analysis of HIV-1 infected patients in Austria

被引:7
作者
Falkensammer, Barbara
Doerler, Martin
Kessler, Harald H.
Puchhammer-Stoeckl, Elisabeth
Parson, Walter
Duftner, Christina
Dierich, Manfred P.
Stoiber, Heribert
机构
[1] Innsbruck Med Univ, Dept Hyg Microbiol & Social Med, A-6020 Innsbruck, Austria
[2] Med Univ Graz, Inst Hyg, Graz, Austria
[3] Med Univ Vienna, Inst Virol, Vienna, Austria
[4] Innsbruck Med Univ, Inst Legal Med, Innsbruck, Austria
[5] Innsbruck Med Univ, Dept Internal Med, Innsbruck, Austria
关键词
HIV-1; subtypes; Austria; circulating recombinant forms; genotypic resistance;
D O I
10.1007/s00508-006-0745-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Analysis of HIV-1 subtypes and genotypic resistance have been shown to be relevant for epidemiologic and therapeutic studies or for vaccine development. In Europe, the majority of HIV-1 isolates belong to subtype B. Due to migration an increasing incidence for additional subtypes and complex recombinant forms are expected. OBJECTIVES AND STUDY DESIGN: To evaluate the prevalence of HIV-1 subtypes in Austria, 188 plasma samples of treatment experienced patients were investigated. For phylogenetic analysis protease and reverse transcriptase genes were amplified and sequenced. Subtypes were determined by comparing reference sequences. For genotypic resistance determination, the Resistance-Algorithm-Comparison from Stanford University was used. RESULTS: Non-B subtypes were found in 20.2% of all patients with a dominant prevalence (50%) in the Southern provinces of Austria. With 85% CRF01_AE and CRF02_AG are the predominant circulating recombinant forms in Austria. When resistance mutations were analyzed, 57.4% of all patients were susceptible to all three groups of antiretroviral drugs, whereas in 12.2% resistance against all three classes of antiretroviral drugs was found. CONCLUSION: HIV-1 subtype B is still dominant in major parts of Austria. However, a significantly increasing percentage of non-B subtypes and recombinant forms are observed in the Southern provinces.
引用
收藏
页码:181 / 185
页数:5
相关论文
共 28 条
[21]  
Renjifo B, 2001, J HUMAN VIROL, V4, P16
[22]   Genotypic testing for human immunodeficiency virus type 1 drug resistance [J].
Shafer, RW .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (02) :247-+
[23]   Molecular epidemiology of HIV: Tracking AIDS pandemic [J].
Takebe, Y ;
Kusagawa, S ;
Motomura, K .
PEDIATRICS INTERNATIONAL, 2004, 46 (02) :236-244
[24]   The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools [J].
Thompson, JD ;
Gibson, TJ ;
Plewniak, F ;
Jeanmougin, F ;
Higgins, DG .
NUCLEIC ACIDS RESEARCH, 1997, 25 (24) :4876-4882
[25]   Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into western countries [J].
Thomson, MM ;
Nájera, R .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (12) :1732-1737
[26]  
TOMASO H, 1995, WIEN KLIN WOCHENSCHR, V107, P85
[27]   Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients [J].
Vergne, L ;
Peeters, M ;
Mpoudi-Ngole, E ;
Bourgeois, A ;
Liegeois, F ;
Toure-Kane, C ;
Mboup, S ;
Mulanga-Kabeya, C ;
Saman, E ;
Jourdan, J ;
Reynes, J ;
Delaporte, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :3919-3925
[28]   Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors [J].
Walter, H ;
Schmidt, B ;
Korn, K ;
Vandamme, AM ;
Harrer, T ;
Überla, K .
JOURNAL OF CLINICAL VIROLOGY, 1999, 13 (1-2) :71-80